Screener Summaries Updates Institutions Sign In More Updates › Financing › AIM Financing · Sep 10, 2026
AIM ImmunoTech Inc. entered into exchange agreements with Streeterville Capital, LLC to convert approximately $450,000… AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc. entered into exchange agreements with Streeterville Capital, LLC to convert approximately $450,000 of outstanding debt under a November 2025 promissory note into 1,921,441 shares of common stock at an average conversion price of $0.234 per share. This transaction was approved by stockholders at a special meeting on July 15, 2026. The company operates in the biotechnology industry, focusing on immunotherapy treatments.
More from AIM ImmunoTech Inc. AIM ImmunoTech releases investor presentation highlighting Ampligen opportunity in pancreatic cancer Nov 5, 2026 AIM ImmunoTech Inc. converted approximately $400,000 of its outstanding Promissory Note into 1,749,434 shares of… Sep 14, 2026 AIM ImmunoTech Inc. converted approximately $1,224,341 of outstanding debt under a Promissory Note dated February 16… Sep 4, 2026 AIM ImmunoTech Inc. received a letter from NYSE Regulation on June 12, 2026, confirming the company has regained… Jun 15, 2026 AIM ImmunoTech Inc. entered into a securities purchase agreement on June 9, 2026, to conduct a registered direct… Jun 11, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
